Monograph Capital
Life sciences venture investor turning promising science into new treatments
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Series A, Series B+
- Sector focus
- Healthtech, Biotech & Life Sciences, Hardware & Robotics
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Website
- monograph.bio
Monograph Capital is a life sciences investor that finds and funds companies developing new treatments for patients. It describes itself as a transatlantic team and points to differentiated sourcing, long-standing relationships with pharmaceutical companies, medical expertise and operating experience as its strengths.
Its UK arm, Monograph Capital Advisors (UK) LLP, is an appointed representative of an FCA-regulated firm. Industry profiles report that the firm was founded in 2021, has offices in London and San Francisco and invests in therapeutics and pharma services businesses; it co-founded Elevara Medicines, which raised a Series A in 2025.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.